Journal of Medicinal Chemistry · 1996 · 33 citations · 18 references
MedicineMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyAntipsychotic PharmacotherapyAntipsychotic TherapyDopaminergic PharmacologySerotonergic PharmacologyStructure-activity Relationship AnalysisAnimal Disease ModelsAntipsychotic ActionAtypical Antipsychotic TreatmentDopamine D2-like ReceptorsLigand-receptor AffinityMedicinal HeterocyclesPharmacological ProfilingSerotonin Receptor Pharmacology
HP-236 (3-[4-[4-(6-Fluorobenzo[b]thien-3-yl)-1-piperazinyl]butyl]-2,5,5- trimethyl-4-thiazolidinone maleate; P-9236) (54) displayed a pharmacological profile indicative of potential atypical antipsychotic activity. A series of piperazinyl butyl thiazolidinones structurally related to this compound were prepared and evaluated in vitro for dopamine D2 and serotonin 5HT2 and 5HT1A receptor affinity. The compounds were examined in vivo in animal models of potential antipsychotic activity and screened in models predictive of extrapyramidal side effect (EPS) liability. The synthesis of these compounds, details of their structure-activity relationships, and discovery of a new lead, compound 50, as well as further development of the profiles of compounds 50 and 54 are described.
18
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1
Roger K. Sunahara, Hong‐Chang Guan, Brian F. O’Dowd et al. · Nature · 1991 · 1.2K citations · Full text